TribLIVE

| Lifestyles

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Local diabetes study earns spotlight

Email Newsletters

Click here to sign up for one of our email newsletters.

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

Thursday, Nov. 15, 2007
 

Safety trials of a medical technique that could reverse Type 1 diabetes might be completed by year's end at Children's Hospital of Pittsburgh, the lead researcher told diabetes experts gathered Wednesday in Miami.

"We've had very positive results so far," Dr. Massimo Trucco, director of immunogenetics at Children's Hospital, said about the first phase of the trials that are testing the technique's safety. "We have to first prove that this is safe. When we pass that goal, the second step will be to prove its efficacy."

The trials, which began in July, involve injecting patients with their own immune cells -- after they have been genetically altered so they can block the destruction of insulin-producing cells in the pancreas.

Such a technique has proven effective in mice. Trucco and his colleagues are eager to test the technique in children -- a population at high risk of developing Type 1 diabetes.

The trials do not involve children. Instead, researchers are using the technique on 18-year-olds who are able to give consent to the experiments. Five people have been enrolled so far, and four of them have started to receive the injections. Trucco's goal is to enroll 10 more people in the trial.

None of the participants has shown any sign of side effects, such as rash or fever, said Trucco, who also is a professor of pediatrics at the University of Pittsburgh.

If successful, the technique could be a weapon against Type 1 diabetes -- a disease that robs people of their ability to produce insulin and forces them to rely on daily doses of insulin to survive.

The research at Children's was one of several approaches discussed over the past four days at a meeting of the Type 1 Diabetes TrialNet Study Group -- which includes researchers from more than 150 medical centers in the United States, Canada, Europe and Australia.

Trucco said more extensive studies of the technique's efficacy could start in the spring.

The injections are made with so-called dendritic cells isolated from the patient's own blood. Study participants receive three injections a week for six weeks. Half of the participants are in a control group, which means they are getting injections of cells that have not been altered.

Subscribe today! Click here for our subscription offers.

 

 

 


Show commenting policy

Most-Read Stories

  1. Peduto blasts Wolf’s plan to borrow $3B to shore up pensions
  2. Steelers notebook: LB Dupree sits out backs-on–backers drill
  3. Inside the Steelers: Williams’ quickness out of backfield evident in drills
  4. Starkey: Garoppolo baffles Steelers
  5. Man arrested in Marshall-Shadeland barbershop killing
  6. Preseason honors piling up for former Pitt tackle Bisnowaty
  7. Extremes in weather hurt crops in Westmoreland
  8. Tight ends’ role in Steelers passing game continues to lessen but players remain selfless
  9. United Airlines hack coincided with incursion into government employee data
  10. Beaver County widow won’t lose home over $6.30 late fee
  11. Plastics propel Bayer’s 2Q earnings